Using the Our Future Health data resource for research
UK Research and Innovation’s Medical Research Council runs a pilot in which eligible MRC-funded researchers can access the Our Future Health data resource, with MRC covering data access costs while researchers handle compute and external fees.
Using the Our Future Health data resource for research
The UKRI opportunity page presents this as an active pilot run through the MRC: “Using the Our Future Health data resource for research”. It is not a classical grant with competitive rounds and broad budget categories. It is a specific pathway to lower the barrier to one of the major long-running problems in health research: gaining timely access to a deep, harmonised dataset for serious disease prediction and prevention work without having to build your own data access infrastructure from scratch.
The page shows the opportunity as open from 23 March 2026 and states there is no fixed closing date. On a practical level, this means the scheme is running as an invitation-based pilot while demand is managed. The available pool is explicitly finite, and UKRI signals that a closing date could be introduced if application volumes increase. So, while it reads as “open,” it should be treated as a narrow-bandtime window that rewards readiness, not waiting.
At a glance
| Field | Details |
|---|---|
| Title | Using the Our Future Health data resource for research |
| Funder | Medical Research Council (MRC), UKRI |
| Co-funder | Our Future Health |
| Funding type | Other (pilot access-support mechanism) |
| Total budget | £1,000,000 |
| Application status | Open (rolling / no closing date) |
| Eligibility core | MRC-supported researchers or researchers at MRC-funded institutes/units |
| Geographic availability | UK-focused for the pilot, with explicit country/territory restrictions for outside use |
| Core support | MRC covers data access costs for approved applications |
| Not covered | Compute costs are billed separately; users may need to pay OFH data access fees |
| Publication/launch date | 23 March 2026 |
| Contact | [email protected] |
What this opportunity is (and what it is not)
This is a structured, two-stage access route rather than a broad call for proposals. The central objective is to make MRC-supported researchers aware of a pathway to work with the Our Future Health dataset and receive partial financial support for it.
The official UKRI page clarifies that this pilot is aimed at studies that can help discover or test better approaches to predicting, detecting, and treating major diseases within the MRC remit for improving human health. It is not a blanket technology grant, innovation incubator, or entrepreneurship stipend. The benefit is specifically tied to data access costs and the dataset workflow.
The page also states the pilot is finite. That matters. A finite pool means selection pressure is operational, even though there is no fixed deadline. Review throughput and demand management can shape practical odds. The strongest practical strategy is to treat this as if there is a hidden shortlist and submit polished materials early, with complete compliance details.
Who should seriously consider applying
You should only apply if all of these are true:
- You are genuinely linked to the MRC funding ecosystem.
- Your proposed study is directly in the remit of an MRC-supported health research programme.
- You can progress through both an MRC expression-of-interest workflow and the Our Future Health application workflow.
Confirmed eligibility from UKRI
The UKRI opportunity sets out a concise acceptance set:
- Researchers supported by an MRC grant.
- Researchers based at an MRC-funded institute or unit.
- Senior researchers on behalf of MRC-supported students or fellows, where most of the trainee funding is from MRC.
It also adds a practical gate: access depends on country and territory eligibility on the OFH side. UKRI explicitly points non-UK applicants to the OFH country/territory access page before investing in documents.
Strong fit profile
A proposal is strongest when it maps clearly to disease-focused or prevention-oriented aims and has a clear data-use logic:
- Clear scientific question with direct use of OFH phenotypes/linked data.
- A method that improves prediction or clinical understanding in a measurable way.
- A scope that can complete in a 1–2 year study window.
- Evidence of team capacity for secure TRE analysis and governance.
Weak fit profile
Teams often fail when they try to repurpose the scheme for:
- Non-health/health-adjacent projects outside MRC remit.
- Exploratory work that does not define a specific study requiring OFH data.
- Vague one-paragraph intents with no concrete deliverables or analysis design.
Timeline and cadence
Because there is no closing date, timing is driven by stage completion:
- UKRI receives expression of interest (EOI) from eligible researcher(s).
- If eligible, MRC confirms and then points the researcher into the OFH process.
- OFH applies its own registration + study application workflow.
The sources include concrete expectation windows:
- OFH says you should receive a response to researcher registration requests within about 2 weeks.
- UKRI says EOI eligibility decisions can take up to 4 weeks.
- The OFH Access Board process for study approval can take up to 60 days.
Why this matters
Because no single hard deadline exists, delays are mostly caused by incomplete submissions, missing terms acknowledgements, or governance gaps that trigger review loops. If you already know your study direction, the biggest risk is administrative friction. A clean package with governance evidence usually moves faster.
Funding and cost logic (critical)
What MRC covers
The UKRI page states MRC will cover data access costs. This is the real grant benefit and is usually the reason teams apply.
What MRC does not cover
From the OFH process guidance and UKRI page:
- Compute costs are billed separately by OFH’s platform/partners.
- OFH may provide nominal cloud credits to studies to help initial setup (explicitly noted as available up to at least 31 August 2027).
- Commercial organisations may face different fee structures.
It is useful to separate this in your internal budget model: this is a data-access subsidy, not a full project budget. If your study relies on sustained compute at scale, your institutional cost coverage plan must be explicit and independent from the grant’s MRC contribution.
Duration expectations
UKRI sets expected study duration at one to two years. If your plan is longer, you may need to justify a phased data use and staged analyses across approved windows.
Two-stage application process (how it actually works)
This opportunity uses a staged mechanism. The UKRI page presents this clearly:
- Submit expression of interest to MRC.
- On eligibility confirmation, register and apply through OFH study process.
That broad outline hides important implementation detail. The OFH process page adds the exact sequence. Build around it from day one.
Stage 1: MRC expression of interest
The UKRI page requires submission of the EOI to MRC and includes a DOCX form request covering current MRC funding references and alignment to current and future MRC priorities.
For submission quality:
- Ensure PI and team details exactly match MRC grant records.
- Clarify whether the project is linked to an existing MRC award.
- Briefly tie your aims to disease outcomes and prevention/detection pathways.
If accepted to stage two, your file should already be strong enough to pass into OFH requirements without major revisions.
Stage 2: OFH researcher registration
The OFH page says you create a researcher account, then apply as a registered researcher. It is not just a login form; it is a governance gate:
- You must submit the researcher form.
- You must agree to Registered Researcher Terms.
- You need recent UK GDPR training (or evidence of equivalent training).
The page sets an expected response time around 2 weeks for registration checks.
Stage 3: Study application and approval
After registration, you submit the study application in the OFH portal. Required elements include:
- clear study summary and data scope,
- collaborators and associated organisations,
- organisational sign-off,
- signed resource terms,
- international data transfer paperwork when needed.
If your work is outside UK/EEA and outside adequacy-country status, an IDTA is required. OFH mentions this explicitly.
Stage 4: Access and compliance lifecycle
Once approved, your data usage proceeds in a secure environment and OFH expects continued reporting:
- annual study progress reports,
- updates for amendments,
- publication declaration and compliance with publication policy.
The system is built to enforce this as a research-cycle process, not a one-off data download.
What reviewers and reviewers’ equivalents typically look for
This is not a scorecard-style panel exercise in the same way as a grant round, but selection still has clear gates. The quality signal is usually:
- clear MRC alignment,
- specific, feasible scientific question,
- governance readiness (registration, terms, approvals,
- data minimisation and ethical clarity,
- evidence of collaboration capability.
Because this is a finite pilot, clarity and speed matter more than polished aesthetics. A project that explains exactly what it will do with the data, in one sentence plus one page, often outranks long generic narratives.
Common mistakes (high-priority failure modes)
- Treating it as a generic data request.
The opportunity is tied to MRC support and health-research outcomes. Applications that do not foreground this are usually deprioritised.
- Skipping the MRC-first workflow.
Some teams build OFH forms before receiving MRC confirmation. That creates rework and delays and can produce expiry of internal timelines.
- Under-specifying compute and infrastructure needs.
Since compute can be outside MRC support, reviewers and administrators will ask how the team sustains analysis. If compute is not budgeted and governance-cleared, review committees may question feasibility.
- **Ignoring collaborator verification.
OFH requires that each collaborating researcher be a registered researcher too. Teams that forget this run into avoidable loops.
- **Assuming no international compliance burden.
Outside UK/EEA access may require IDTA. Treat this as a pre-submission check, not a late-stage adjustment.
- **Unclear change-management strategy.
If scope changes during a study, OFH expects notification and amendment handling. Teams that do not set this up in advance can get delayed midstream.
Strategic preparation checklist
Use this as a practical prep list:
- Confirm MRC funding alignment before drafting any long proposal text.
- Prepare a one-page scientific memo in advance: question, population, variables, analysis outcome, and expected deliverable.
- Identify your TRE compute path and budget assumptions for at least the first year.
- Get your PI and institutional representative ready to sign required terms early.
- Build GDPR and data governance evidence into your onboarding package.
- If using collaborators outside UK/EEA, start IDTA mapping before submission.
- Keep study summaries in plain language as required; review your phrasing.
The EOI and study form process rewards concise evidence. If you cannot explain your study in one clear paragraph with a direct data-access need, it is usually not submission-ready.
Frequently asked questions
Is this only for clinical medicine?
The stated scope is MRC health remit research and disease-focused discovery/translational questions. It is not restricted to patient-only clinical trials, but it is not expected to be unrelated to health outcomes.
Is there a fixed deadline I can calendar?
The UKRI page explicitly lists open - no closing date and notes the pilot may close when volume thresholds trigger a review.
Can students apply?
Students are included indirectly via senior researchers on behalf of MRC-supported students/fellows where appropriate. They cannot usually bypass principal-level eligibility requirements.
How long before I can access data?
Expect sequential waiting windows (MRC decision + OFH review), so timelines can extend significantly if materials are incomplete.
Will data access be instant?
No. This is a controlled access workflow with registration, review, and compliance checks.
Practical decision rule
If your team has an MRC-linked disease project with clear data-driven analysis and no strong alternative dataset available at this scale, this is one of the clearest near-term pathways to add high-value evidence infrastructure support. If you do not yet have MRC-linked funding, treat it as a downstream possibility only after you identify a suitable institutional route.
A useful internal test is this: Can you truthfully answer all of the following before pressing submit?
- Is my study exactly within the MRC-supported health scope?
- Do I have all org-level governance evidence ready?
- Do I understand who pays what (data access vs compute)?
- Can I keep the study within 1–2 years?
If any answer is “no,” fix that first.